SCHEMBL1367579

SCHEMBL1367579

Cc1nc(Cl)c2ccsc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPT P10636 1/20 0.50
PKM P14618 1/20 0.50
HTR2C P28335 1/20 0.47
CYP2C19 P33261 3/20 0.44
CYP2D6 P10635 2/20 0.44
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 1/20 0.40
ADORA2A P29274 2/20 0.39
HTT P42858 1/20 0.37
ADORA1 P30542 1/20 0.37
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
DAPK3 O43293 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3445188 0.79 MAPK1 (0.54) KMT2AMAPK1HSD17B10L3MBTL1ALDH1A1
SCHEMBL1182070 0.79 HTR2C (0.50) KMT2AMAPK1HSD17B10L3MBTL1ALDH1A1
SCHEMBL10292506 0.76 MAPK1 (0.51) KMT2AMAPK1HSD17B10L3MBTL1ALDH1A1
SCHEMBL5313613 0.76 MAPK1 (0.51) KMT2AMAPK1HSD17B10L3MBTL1ALDH1A1
SCHEMBL17181116 0.76 ADORA2A (0.55) KMT2AMAPK1HSD17B10L3MBTL1ALDH1A1
SCHEMBL10245410 0.76 DYRK1A (0.49) KMT2AALDH1A1HTR2CCYP2C19CYP2D6
SCHEMBL20659859 0.76 HTR2C (0.44) KMT2AALDH1A1SMN1; SMN2MAPTPKM
SCHEMBL31044797 0.76 HTR2C (0.44) KMT2AALDH1A1SMN1; SMN2MAPTPKM
SCHEMBL3234762 0.76 KMT2A (0.45) KMT2AMAPK1HSD17B10L3MBTL1ALDH1A1
SCHEMBL15627224 0.73 MAPK1 (0.49) KMT2AMAPK1HSD17B10L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281126-B2 Inhibitors of cyclin-dependent kinase 7 and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-04-22 US disclosed
WO-2024131942-A1 CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海深势唯思科技有限责任公司 2024-06-27 WO disclosed
CN-118239926-A TLR7 and 8 inhibitors, preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 CN disclosed
CN-118239959-A Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 CN disclosed
WO-2024048714-A1 METHOD FOR PRODUCING 6-(4,4-DIMETHYLCYCLOHEXYL)-4-[(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)METHYL]-2-METHYLTHIENO[2,3-D]PYRIMIDINE OR SALT THEREOF アステラス製薬株式会社 2024-03-07 WO disclosed
US-20240002395-A1 COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN THE JOHNS HOPKINS UNIVERSITY 2024-01-04 US disclosed
US-20230148450-A9 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2023-05-11 US disclosed
US-20230148450-A9 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2023-05-11 US disclosed
US-20230138901-A1 COMPOUND HAVING KHK INHIBITORY EFFECT HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2023-05-04 US disclosed
US-20220135584-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF REVOLUTION MEDICINES INC (US) 2022-05-05 US disclosed
WO-2008090140-A1 ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS 4SC AG (DE) 2008-07-31 WO disclosed
EP-1947103-A1 Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments 4SC AG (DE) 2008-07-23 EP disclosed
EP-1838718-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS Pfizer, Inc. (US) 2007-10-03 EP disclosed
US-20070213305-A1 N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-09-13 US disclosed
US-20070213305-A1 N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-09-13 US disclosed
US-20070213305-A1 N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-09-13 US disclosed
WO-2007056214-A2 N-ALKYL-N-ARYL-THIENOPYRIMIDIN-R-AMINES AND USES THEREOF CYTOVIA, INC (US) 2007-05-18 WO disclosed
WO-2007056214-A2 N-ALKYL-N-ARYL-THIENOPYRIMIDIN-R-AMINES AND USES THEREOF CYTOVIA, INC (US) 2007-05-18 WO disclosed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed
WO-2006072831-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PFIZER INC. (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281126-B2 Inhibitors of cyclin-dependent kinase 7 and uses thereof CDK9, CDK7, CDK1 KMT2A 2719/4885MAPK1 199/4885HSD17B10 3105/4885
US-20070213305-A1 N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP10, CASP4, CASP3 KMT2A 2940/4885MAPK1 2659/4885HSD17B10 1503/4885
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, API5 KMT2A 3038/4885MAPK1 2419/4885HSD17B10 2920/4885
US-20240002395-A1 COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN MRGPRX1, MRGPRX4, MRGPRX2 KMT2A 3290/4885MAPK1 1494/4885HSD17B10 4685/4885
US-20230138901-A1 COMPOUND HAVING KHK INHIBITORY EFFECT KHK, KHDRBS1, KHSRP KMT2A 447/4885MAPK1 731/4885HSD17B10 943/4885
US-20220135584-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 KMT2A 4618/4885MAPK1 1815/4885HSD17B10 3031/4885
US-20230148450-A9 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 KMT2A 4618/4885MAPK1 1815/4885HSD17B10 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.